Bristol-Myers Squibb Co news

   Watch this stock
Showing stories 1 - 10 of about 69   

Articles published

BMY 61.30 +0.51 (0.84%)
price chart
BBDO, CDM Said to Win Big Bristol-Myers Squibb Brand
Omnicom agencies BBDO New York and The CDM Group have been given U.S. creative lead responsibilities for Bristol-Myers Squibb's Abilify antidepressant drug, sources said. The brand, which had been at Digitas Health, spent $133.7 million in U.S. ...
Bristol-Myers Squibb - Abilify
And finally... There is Bristol-Myers ($BMY) and its bad behavior. Its 2007 settlement covered a number of violations, such as gaming the system to jack up prices on Serzone.
Bristol-Myers Squibb a Top 25 Dividend Giant With 3.88% Yield
Bristol-Myers Squibb Co. (NYSE: BMY) has been named as a Top 25 �Dividend Giant� by ETF Channel, with a stunning $2.26B worth of stock held by ETFs, and above-average �DividendRank� statistics including a strong 3.88% yield, according to the most ...
Bristol-Myers Squibb to acquire Amylin for USD 5.3 billion  Economic Times
Jonathan D. Rockoff  Wall Street Journal
Related articles »  
Bristol-Myers Squibb and Pfizer Receive Complete Response Letter from U.S. ...
PRINCETON, N.J. & NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) and Pfizer (NYSE: PFE) announced that the U.S.
Pfizer, Bristol-Myers Squibb receive FDA CRL for ELIQUIS NDA  News-Medical.net
FDA Unexpectedly Delays Move on Anticlotting Drug  New York Times
Related articles »  
Dying man fights to get experimental drug from Bristol-Myers Squibb
The company empathizes with patients who have limited treatment options, said spokeswoman Sonia Choi in a statement Sunday.
Related articles »  
Interim results from Bristol-Myers Squibb's BMS-936558 Phase 1 study on ...
Bristol-Myers Squibb Company (NYSE: BMY) today announced interim results from the expanded Phase 1 dose-ranging study 003 (n=296) of its investigational anti-PD-1 immunotherapy (BMS-936558), which showed clinical activity in patients with ...
Related articles »  
Otsuka, Bristol-Myers Squibb announce six-year data from SPRYCEL Phase 3 ...
Bristol-Myers Squibb Company (NYSE: BMY) and Otsuka Pharmaceutical Europe Ltd., today announced six-year follow-up results from a Phase 3 randomised, open-label, dose-optimisation study of SPRYCEL� (dasatinib) in Philadelphia ...
Related articles »  
Bristol-Myers Immune Drug Puts Deadly Cancers on Hold in Study
The early success of an experimental drug from Bristol-Myers Squibb Co. that's designed to unleash the body's immune-system defenses against cancer sets the stage for an industry wide race to produce similar treatments.
Related articles »  
Medivir, Bristol-Myers Squibb to initiate TMC435 and daclatasvir phase II ...
Medivir AB (OMX:MVIR), the research-based pharmaceutical company focused on the development of high-value treatments for infectious diseases, announces that a phase II combination study with the investigational compound TMC435 and Bristol-Myers ...
Related articles »  
Terminally ill patients should have access to last-chance therapies
His oncologist recommends that he be given the drug, BMS-936558, saying it may help. But Bristol-Myers Squibb has denied the request, saying it has a responsibility to protect patient safety in the research and development of its medicines.